Literature DB >> 10357127

Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin.

Y Sherer1, Y Levy, P Langevitz, M Lorber, F Fabrizzi, Y Shoenfeld.   

Abstract

Neuropsychiatric lupus includes extremely diverse clinical manifestations, ranging from mild cognitive dysfunction to a severe, life-threatening presentation. We report a 28-year-old patient with systemic lupus erythematosus who had persistent fever for 3 months, and developed within a few hours motor and sensory aphasia, rotator nystagmus with deviation of the eyes, and severe nuchal rigidity. An extensive series of imaging and laboratory tests were interpreted as normal, except for an elevated opening pressure at lumbar puncture, cerebrospinal fluid inflammatory findings, and asymmetrical cortical perfusion on single-photon emission computed tomography. The patient received one course of high-dose intravenous immunoglobulin (IVIg) and within 5 days her condition returned to that of 3 months before admission. The mechanisms of injury, along with the management of cerebral lupus and the mechanisms of action of IVIg, are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357127     DOI: 10.1007/s100670050079

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

5.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors:  L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

Review 6.  Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Authors:  Aaron M Milstone; Kevin Meyers; Josephine Elia
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

Review 7.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

8.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors:  Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2006-11-15       Impact factor: 19.103

9.  Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea.

Authors:  I Lazurova; Z Macejova; K Benhatchi; M Oetterová; E Antolová; R A Asherson; J Rovensky
Journal:  Clin Rheumatol       Date:  2007-05-09       Impact factor: 2.980

10.  Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases.

Authors:  Sevil Kamali; Ayse Cefle; Mehmet Sayarlioglu; Ahmet Gul; Murat Inanc; Lale Ocal; Orhan Aral; Meral Konice
Journal:  Rheumatol Int       Date:  2004-01-14       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.